OncoMed Pharmaceuticals, Inc. Granted Additional Broad Anti-RSPO Antibody Patent in U.S.

REDWOOD CITY, Calif., Sept. 25, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the United States Patent and Trademark Office has granted OncoMed its third broad U.S. patent relating to antibodies that target the RSPO-LGR pathway, which is believed to be an important CSC pathway. The new patent, U.S. Patent No. 8,540,989, covers methods of treating cancer with antibodies that bind human R-spondin (RSPO) proteins and either disrupt the binding of such proteins to their receptors, the leucine-rich repeat-containing G-coupled receptors (LGRs), or disrupt RSPO activation of LGR signaling.

Help employers find you! Check out all the jobs and post your resume.